Molecular Formula | C20H17F3N2O4 |
Molar Mass | 406.36 |
Density | 1.427±0.06 g/cm3(Predicted) |
Boling Point | 501.5±50.0 °C(Predicted) |
pKa | 4.50±1.00(Predicted) |
Storage Condition | 2-8°C |
In vitro study | Tasquinimod inhibits tumor angiogenesis through allosteric inhibition of HDAC4/N-CoR/HDAC3-dependent HIF-1α deacetylation. Tasquinimod also targets infiltrating bone marrow cells and modulates local tumor immunity by blocking the interaction of S100A9 with its ligand receptors (advanced glycation end products and Toll-like receptor 4). |
In vivo study | In a mouse model of human and rodent prostate cancer, Tasquinimod (30 mg/kg/d p.o.) exhibited anti-angiogenic effects and thus inhibited tumor growth. |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 2.461 ml | 12.304 ml | 24.609 ml |
5 mM | 0.492 ml | 2.461 ml | 4.922 ml |
10 mM | 0.246 ml | 1.23 ml | 2.461 ml |
5 mM | 0.049 ml | 0.246 ml | 0.492 ml |